Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 410

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development

Open access
Dutta, Noton K., Mazumdar, Kaushiki, Gordy, James T.·2020·Journal of Virology

Abstract

KEYWORDS coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nucleocapsid protein, vaccine D uring the current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been an unprecedented level of global collaboration that has led to a rapid characterization of SARS-CoV-2 (1).Its sequence shares 79.6% identity to SARS-CoV (1, 2), the infectious virus that caused an epidemic in 2003 (2, 3).SARS-CoV-2 has a single-stranded, plus-sense, RNA genome of approximately 30 kb, which includes five major open reading frames encoding nonstructural replicase polyproteins and structural proteins (1), namely, spike (S) (4-6), envelope (E), membrane (M), and nucleocapsid (N) (7), and they are in the same order and of approximately the same sizes as those in SARS-CoV.The SARS-CoV-2 S protein is being used as the leading target antigen in vaccine development (8, 9).However, the complex molecular details of viral entry may lead to complications with the vaccine response, similar to those seen with HIV type 1 (HIV-1) Env protein vaccine efforts (10).The SARS-CoV-2 S gene has 76% amino acid similarity to the SARS-CoV S gene (11), and nonsynonymous mutations developed in the S protein as the SARS-CoV epidemic progressed (12, 13).In contrast, the N gene is more conserved and stable, with 90% amino acid homology and fewer mutations over time (2,3,11,(14)(15)(16). N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection (17).High levels of IgG antibodies against N have been detected in sera from SARS patients (18), and the N protein is a representative antigen for the T-cell response in a vaccine setting, inducing SARS-specific T-cell proliferation and cytotoxic activity (19, 20).We have already shown that the middle or C-terminal region of the SARS-CoV N protein is important for eliciting antibodies against SARS-CoV during the immune response (21-23).New reports have additionally shown that the crystal structure of the SARS-CoV-2 nucleocapsid protein is similar to those of previously described coronavirus N proteins, but their surface electrostatic potential characteristics are distinct (7).Sheikh et al. studied the factors influencing N gene variations among 13 coronaviruses and how these affect virus-host relationships, reporting a high AT% and low GC% in the nucleotide contents of SARS coronavirus (24).In this issue, Cong et al. ( 17) used a mouse hepatitis virus (MHV) model to show that the viral nucleocapsid (N) protein contributes to forming helical ribonucleoproteins during the packaging of the RNA genome, regulating viral RNA synthesis during replication and transcription and modulating metabolism in infected subjects.This study complements others that have shown N to have multiple functions (25).It is becoming more evident just how critical this protein is for multiple steps of the viral life cycle.These reports offer important and timely insights relevant to the SARS-CoV-2 N protein, a vaccine target that has some distinct advantages over other potential SARS-CoV-2 antigens.Because of the conservation of the N protein sequence, the expanding

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.00647-20

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 410

Metadata

Authors
Dutta, N. K., Mazumdar, K., & Gordy, J. T.
Venue
Journal of Virology
Published
2020-06-16
Volume
94
Issue
13
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W3035051352
Cited by
410
References
21
FWCI
9.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. https://app.cochat.ai/papers/10.1128/jvi.00647-20
The paper
Dutta, N. K., Mazumdar, K., & Gordy, J. T. (2020). The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. Journal of Virology. https://doi.org/10.1128/jvi.00647-20

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.